Tata Elxsi vs Phillips-Medisize: full comparison for 2026
Quick verdict
Tata Elxsi (3.9/5) edges ahead of Phillips-Medisize (3.9/5) overall. Tata Elxsi is the better choice for large medtech firms offshoring sustaining engineering. Phillips-Medisize is the stronger option for drug delivery devices needing high-volume production. The right choice depends on your project size, budget, and required tech stack.
Tata Elxsi vs Phillips-Medisize: head-to-head summary
| Criterion | Tata Elxsi | Phillips-Medisize |
|---|---|---|
| Founded | 1989 | 1964 |
| HQ | Bengaluru, India | Hudson, WI, USA |
| Team size | 13,000+ | ~7,000 |
| Rating | 3.9 / 5 | 3.9 / 5 |
| Primary differentiator | Offshore scale for verification, documentation and sustaining work on existing device portfolios | Design, molding and assembly of drug delivery devices under one global quality system |
| Pricing model | Time and materials, dedicated team, fixed project | Development contract plus manufacturing supply agreement |
| Min. engagement | Not disclosed | Not disclosed |
| Primary tech stack | Embedded C/C++, Embedded Linux, Test automation | Injection molding, Automated assembly, BLE |
| Industries served | Surgical & therapeutic devices, Diagnostics & lab devices, Digital health, Automotive | Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices |
Tata Elxsi vs Phillips-Medisize: overview
Tata Elxsi
Tata Elxsi is a Tata Group engineering and design company founded in 1989 and headquartered in Bengaluru, with more than 13,000 employees across automotive, media and healthcare. Its medical device practice covers hardware, firmware, mechanical engineering, verification and validation and lifecycle management under an ISO 13485:2016 compliant QMS, and it offers pre-submission support for 510(k) and PMA filings. In 2026 it opened an offshore development center for Terumo in Pune and launched AnaTel, an AI tool for preparing regulatory documents.
Phillips-Medisize
Phillips-Medisize is a subsidiary of Molex, itself owned by Koch Industries, and provides outsourced design, development and manufacturing to pharma, diagnostics and medical device companies. It is based in Wisconsin and has about 7,000 employees. Molex's purchase of inhalation specialist Vectura added combination-product expertise, and the combined team includes more than 1,200 engineers and scientists across 30 sites. A $110M manufacturing campus in Katowice, Poland, opened in November 2023.
Services and capabilities: Tata Elxsi vs Phillips-Medisize
| Capability | Tata Elxsi | Phillips-Medisize |
|---|---|---|
| Electronics & PCB design | ✓ | ✓ |
| Firmware & embedded software | ✓ | ✗ |
| SaMD & companion apps | ✓ | ✗ |
| Connected devices & IoT | ✗ | ✗ |
| Industrial design & human factors | ✗ | ✗ |
| Mechanical engineering | ✓ | ✓ |
| Device cybersecurity | ✗ | ✗ |
| Regulatory & QMS support | ✓ | ✓ |
| Manufacturing & scale-up | ✗ | ✓ |
Tech stack comparison: Tata Elxsi vs Phillips-Medisize
| Framework / platform | Tata Elxsi | Phillips-Medisize |
|---|---|---|
| Embedded C/C++ | ✓ | N/A |
| Embedded Linux | ✓ | N/A |
| RTOS | N/A | N/A |
| BLE | N/A | ✓ |
| Cloud (AWS/Azure) | ✓ | N/A |
| IEC 62304 | ✓ | N/A |
| ISO 14971 | ✓ | N/A |
| ISO 13485 QMS | N/A | ✓ |
| Qt | N/A | N/A |
Pricing comparison: Tata Elxsi vs Phillips-Medisize
| Criterion | Tata Elxsi | Phillips-Medisize |
|---|---|---|
| Minimum engagement | Not disclosed | Not disclosed |
| Engagement models | Dedicated team, Fixed project, Time & materials | Fixed project, Manufacturing contract |
| Rate transparency | Not public | Not public |
| Price tier | Mid-market | Mid-market |
Target audience comparison: Tata Elxsi vs Phillips-Medisize
| Dimension | Tata Elxsi | Phillips-Medisize |
|---|---|---|
| Best company size | Startup to mid-market | Startup to mid-market |
| Best industries | Surgical & therapeutic devices, Diagnostics & lab devices, Digital health | Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices |
| Best use cases | Sustaining engineering for a portfolio of cleared devices, EU MDR technical file remediation | Autoinjector or pen injector development and production, Inhaler device for a pharma combination product |
| Typical project type | Dedicated team | Fixed project |
Tata Elxsi vs Phillips-Medisize: pros and cons
| Tata Elxsi | |
|---|---|
| + | Can staff large verification, documentation and sustaining teams |
| + | Offshore development centers for major medtech clients such as Terumo |
| + | Supports 510(k) and PMA preparation |
| + | Lower cost per engineer than Western firms |
| - | Large generalist where healthcare competes with automotive and media for attention |
| - | Better suited to established portfolios than to early-stage invention |
| - | Offshore delivery needs strong client-side technical ownership |
| Phillips-Medisize | |
|---|---|
| + | Very large manufacturing footprint across the US, Europe and Asia |
| + | Vectura deal added deep inhalation and combination-product skills |
| + | Development and manufacturing under one quality system |
| + | Experience with connected drug delivery |
| - | Owned by Molex and Koch Industries, so it suits large pharma more than small startups |
| - | Development work is usually tied to a manufacturing agreement |
| - | Less suited to software-heavy or early research projects |
Who should choose Tata Elxsi?
A typical fit: sustaining engineering for a portfolio of cleared devices.
Offshore scale for verification, documentation and sustaining work on existing device portfolios. Minimum engagement is not publicly disclosed. Works best with clients in Surgical & therapeutic devices, Diagnostics & lab devices, Digital health, Automotive.
Who should choose Phillips-Medisize?
A typical fit: autoinjector or pen injector development and production.
Design, molding and assembly of drug delivery devices under one global quality system. Minimum engagement is not publicly disclosed. Works best with clients in Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices.
Decision matrix: Tata Elxsi vs Phillips-Medisize
| Your situation | Recommended choice |
|---|---|
| You need full-ownership delivery on a defined project scope | Tata Elxsi |
| You need a large dedicated team for an ongoing programme | Tata Elxsi |
| Your budget is at the lower end | Compare: Tata Elxsi (Not disclosed) vs Phillips-Medisize (Not disclosed) |
| You need specialist depth in a specific vertical | Tata Elxsi |
| You need staff augmentation or team extension | Neither; consider alternatives that offer staff aug |
| You need consulting before committing to a build | Both may offer discovery engagements |
Use case fit: Tata Elxsi vs Phillips-Medisize
| Use case | Tata Elxsi fit | Phillips-Medisize fit | Winner |
|---|---|---|---|
| Sustaining engineering for a portfolio of cleared devices | Strong | Limited | Tata Elxsi |
| EU MDR technical file remediation | Strong | Limited | Tata Elxsi |
| Autoinjector or pen injector development and production | Limited | Strong | Phillips-Medisize |
| Inhaler device for a pharma combination product | Limited | Strong | Phillips-Medisize |
Verdict: Tata Elxsi vs Phillips-Medisize
Tata Elxsi (3.9/5) is the stronger overall choice for most Medical Device Development projects. Offshore scale for verification, documentation and sustaining work on existing device portfolios.
Phillips-Medisize (3.9/5) is worth a look if you need inhaler device for a pharma combination product. If your situation matches that, Phillips-Medisize is a competitive option.
Related comparisons
Tata Elxsi vs Phillips-Medisize FAQ
Is Tata Elxsi better than Phillips-Medisize?
Tata Elxsi (3.9/5) scores higher overall, but "better" depends on your use case. Tata Elxsi's strongest advantage: can staff large verification, documentation and sustaining teams. Phillips-Medisize's strongest advantage: very large manufacturing footprint across the US, Europe and Asia.
How do Tata Elxsi and Phillips-Medisize differ in pricing?
Tata Elxsi uses time and materials, dedicated team, fixed project pricing. Phillips-Medisize uses development contract plus manufacturing supply agreement pricing. Neither firm publishes a full rate card; a discovery call is required for project-specific quotes.
Which is better for enterprise: Tata Elxsi or Phillips-Medisize?
Tata Elxsi is the larger team and typically the better enterprise-scale choice. For very large programmes, verify team size and compliance coverage directly with each company before shortlisting.
What are the main differences between Tata Elxsi and Phillips-Medisize?
Tata Elxsi's primary differentiator is: offshore scale for verification, documentation and sustaining work on existing device portfolios. Phillips-Medisize's primary differentiator is: Design, molding and assembly of drug delivery devices under one global quality system. They also differ in team size (13,000+ vs ~7,000), minimum engagement (Not disclosed vs Not disclosed), and primary industries served (Surgical & therapeutic devices, Diagnostics & lab devices vs Drug delivery, Diagnostics & lab devices).
Verify all details directly with each company before making a decision.